CTLA4 and metastatic melanoma: The emergence of new therapies such as immune checkpoint inhibitors (ICI), represented by anti-PD1 and anti-CTLA4, have improved the overall survival (OS) and progression-free survival (PFS) of patients with advanced and metastatic melanoma and are now validated for their therapeutic management [4,5,6].